AKT1 and type 2 diabetes nephropathy: Su et al. (2021) reported that in type 2 diabetic nephropathy, Ginsenoside Rh1 can inhibit inflammation and apoptosis through the AMPK/PI3K/AKT pathway, thereby improving the disease.